PDCD1 and neoplasm: High-dose crizotinib induces immunogenicity in tumor cells and increases the expression of PD1, LAG3, and PDL1, in a mouse model for lung cancer, therefore preparing the tumors for immunotherapy with anti-PD1 antibodies (59).